期刊文献+

抑制RhoA基因表达诱导乳腺癌细胞凋亡的实验研究 被引量:3

Inhibiting RhoA expression to induce apoptosis of breast cancer cells
下载PDF
导出
摘要 目的探讨抑制RhoA基因表达诱导乳腺癌(BC)细胞凋亡的作用。方法通过已建立的RhoA腺病毒载体系统,感染BC MCF-7细胞。经过细胞培养、病毒滴度等,将收集的样本分别用Western blot、RT-PCR技术检测RhoA蛋白表达和基因表达变化;对感染Adsi RNA-RhoA的BC细胞进行MTT检测及细胞内DNA片段化检测。结果腺病毒siRNA-RhoA感染BC细胞能明显抑制RhoA基因表达(抑制率为75.64%),降低RhoA基因的mRNA转录水平69.44%。MTT检测结果表明,感染腺病毒Adsi RNA-RhoA组的肿瘤细胞生长、增殖被明显抑制。TUNEL检测显示,抑制RhoA基因表达能明显导致BC细胞凋亡。结论利用siRNA抑制BC细胞中RhoA基因表达,能诱导BC细胞凋亡。 Objective To investigate the role of RhoA gene inhibition in inducing the apoptosis of breast cancer (BC) cells.Methods Based on a previously constructed adenoviral vector-mediated siRNA system, we infected the BC MCF-7 cells.After cell culture and virus titer measurement experiment , we collected the virus sample .Then Western blot -ting and RT-PCR were used to detect the expression levels of protein and mRNA , respectively .MCF-7 cells were infected by Adsi RNA-RhoA and detected by using MTT and DNA fragmentation assays .Results The Adsi RNA-RhoA infected BC cells significantly inhibited the expression of RhoA gene ( the inhibition rate 75.64%) and reduced the transcriptional level of RhoA mRNA (69.44%).MTT assay revealed that the growth and proliferation of MCF-7 cells infected by Adsi RNA-RhoA was inhibited .TUNEL assay indicated that Adsi RNA-RhoA could induce the apoptosis of MCF-7 cells.Con-clusion Using siRNA to inhibit the expression of RhoA gene in BC cells can induce the apoptosis of BC cells .
出处 《山东医药》 CAS 2014年第21期4-6,共3页 Shandong Medical Journal
关键词 乳腺肿瘤 RHOA基因 细胞凋亡 siRNA breast carcinoma RhoA gene small interfering RNA apoptosis
  • 相关文献

参考文献12

  • 1Hall A. Rho GTPases and the control of cell behaviour[ J]. Bio- chem Soc Trans, 2005,33(5) :891-895.
  • 2Chang YW, Bean RR, Jakobi R. Targeing RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression [ J ]. Recent Pat Anticancer Drug Discov, 2009,4 (2) : 110-124.
  • 3郁玲玲,顾建英.Rho亚家族在肿瘤侵袭中的作用研究进展[J].复旦学报(医学版),2010,37(5):617-619. 被引量:6
  • 4Walker K, Olson MF. Targeting Ras and Rho GTPases as opportu- nities for cancer therapeutics[J]. Curt Opin Genet Dev, 2005,15 ( 1 ) :62-68.
  • 5赵筱倩,刘晓.RhoA、ROCK在乳腺癌组织中的表达及其意义[J].放射免疫学杂志,2012,25(4):439-442. 被引量:5
  • 6李霓,郑荣寿,张思维,邹小农,曾红梅,代珍,陈万青.中国城乡女性乳腺癌发病趋势分析和预测[J].中华预防医学杂志,2012,46(8):703-707. 被引量:144
  • 7李冕,朱嵩,尹昆,刘俏俏,巴再华,张佃波,闫歌.腺病毒siRNA抑制RhoA基因并联合TNF-α诱导肝癌细胞凋亡的研究[J].中国病原生物学杂志,2012,7(2):89-93. 被引量:3
  • 8Xu XT, Song QB, Yao Y, et al. Inhibition of RhoA/ROCK signa- ling pathway promotes the apoptosis of gastric cancer cells [ J ]. Hepatogastroentemlogy, 2012,59(120) :2523-2526.
  • 9Wang H, Zhao G, Liu X, et al. Silencing of RhoA and RhoC ex- pression by RNA interference suppresses human colorectal carcino- ma growth in vivo[J]. J Exp Clin Cancer Res, 2010,29:123.
  • 10Walker K, Olson MF. Targeting Ras and Rho GTPases as opportu- nities for cancer therapeutics[J]. Gun" Opin Genet Dev, 2005,15 ( 1 ) :62-68.

二级参考文献52

  • 1于月成,辛晓燕,吴维光,李红梅,李奇灵.Rho和ROCK蛋白在上皮性卵巢癌中的表达及临床意义[J].现代肿瘤医学,2006,14(4):461-464. 被引量:24
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:278
  • 3李玉阳,洪凡真,王永胜,仲伟霞,左文述.Mammotome在早期乳腺癌原发肿瘤诊断中的应用[J].中华肿瘤防治杂志,2007,14(9):706-708. 被引量:23
  • 4Hua-Wen Sun Shi-Lun Tong Jie He Qi Wang Li Zou Shu-Jing Ma Hai-Yan Tan Jian-Fei Luo Hong-Xue Wu.RhoA and RhoC -siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway[J].World Journal of Gastroenterology,2007,13(25):3517-3522. 被引量:14
  • 5Romond EH,Perez EA,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J] ,N Engl J Med,2005,353(16):1673-1684.
  • 6Ishida T,Kiba T,Takeda M,et al.Phase Ⅱ study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastalic breast cancers resistant to both anthracyclines and taxanes[J].Cancer Chemother Pharmacol,2009,64(2):361-369.
  • 7Scheuer W.Friess T,Burtscher H,et al.Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models[J].Cancer Res,2009,69 (24).-9330-9336.
  • 8Baselga J,Cameron D,Miles D,et,al.Objective response rate in a Phase Ⅱ multicenter trial of pertuzumab(P):a HER2 dimerization inhibiting monoclonal antibody in combination and trastuzumab (T) in patients (Pts)with HER2 positive metastatic breast cancer (MBC) which had progressed during trastuzumabtherapy[J].J Gin Oncol,2007,25 (suppl 18):1004.
  • 9Geyer CE,Forster J,Iindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355 (26):2733-2743.
  • 10Lin Nil,Carey LA,Liu MC,et al.PhaseⅡ trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer[J].J Clin Oncol,2008,26(12):1993 -1999.

共引文献180

同被引文献37

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部